A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer
Anthropometry (1)
- BMI - Body Mass Index at baseline (phv00253374.v1.p1)
Biomarkers (2)
- anc_baseline - ANC value at baseline (phv00253368.v1.p1)
- HGB - Hemoglobin at baseline (phv00253360.v1.p1)
Demographics (2)
- age - Age of participant (phv00253356.v1.p1)
- sex - Gender of participant (phv00253359.v1.p1)
Disease Events (2)
- AFFECTION_STATUS - Case control status of the subject (phv00253344.v1.p1)
- VTE - Case status for venous thromboembolism (phv00253378.v1.p1)
Medications (1)
- anti_plat_coag - Anti-platelet or anti-coagulant use (phv00253371.v1.p1)
Race and Ethnicity (2)
- ethnicity - Ethnicity of participant (phv00253365.v1.p1)
- race - Race of participant (phv00253358.v1.p1)
Substance Use (2)
- currentsmoke - Current smoking status (phv00253370.v1.p1)
- priorsmoke - History of smoking (phv00253369.v1.p1)
Other (35)
- ANALYTE_TYPE - Analyte type (phv00253383.v1.p1)
- anc_cy1cy2 - Neutropenia case status during cycles 1 and 2 of therapy (phv00253377.v1.p1)
- arm - Treatment arm assignment (phv00253357.v1.p1)
- ATE - Case status for Arterial thromboembolism (phv00253380.v1.p1)
- bld_gi_gu - Pre-existing GI or GU perforation or bleeding episode (phv00253372.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00253382.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00253341.v1.p1)
- consent2 - Specimen(s) use for research unrelated to the patient's cancer (phv00253362.v1.p1)
- consent6 - Specimen(s) use for future unknown research related to cancer (phv00253363.v1.p1)
- consent7 - Blood specimen use for genetic research on patient's cancer (phv00253364.v1.p1)
- Diabetes - Indicator of diabetes (phv00253376.v1.p1)
- genetic_euro - Genetic European status (phv00253355.v1.p1)
- GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00253386.v1.p1)
- Hemorrhage - Case status for hemorrhage (phv00253379.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00253385.v1.p1)
- IS_TUMOR - Tumor status (phv00253384.v1.p1)
- Neuro - BSA adjusted cumulative dose to neuropathy event (phv00253351.v1.p1)
- NeuroCens - Neuropathy case status (phv00253352.v1.p1)
- Neut - BSA adjusted cumulative dose to neutropenia event (phv00253353.v1.p1)
- NeutCens - Neutropenia case status (phv00253354.v1.p1)
- PALLXRT - Indicator of palliative radiation (phv00253361.v1.p1)
- prior_ate - Prior history of ATE (phv00253366.v1.p1)
- prior_vte - Prior history of VTE (phv00253367.v1.p1)
- risk_score - Khorana risk status (phv00253375.v1.p1)
- SAMPLE_ID - De-identified sample ID (phv00253381.v1.p1)
- SAMPLE_ID - Sample ID (phv00253346.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00253347.v1.p1)
- SAMPLE_USE - Sample Use (phv00253349.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00253348.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00253343.v1.p1)
- SUBJECT_ID - De-identified subject ID (phv00253350.v1.p1)
- SUBJECT_ID - Subject ID (phv00253340.v1.p1)
- SUBJECT_ID - Subject ID (phv00253345.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00253342.v1.p1)
- ulcer - Pre-existing stomach or duodenal ulcer (phv00253373.v1.p1)